Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01584531
Title Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Onconova Therapeutics, Inc.

bone marrow cancer


Rigosertib Sodium

Age Groups: adult
Covered Countries USA

No variant requirements are available.